Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Boston Scientific Corp (BSX)

Boston Scientific Corp (BSX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 152,462,528
  • Shares Outstanding, K 1,479,070
  • Annual Sales, $ 16,747 M
  • Annual Income, $ 1,854 M
  • EBIT $ 3,461 M
  • EBITDA $ 5,116 M
  • 60-Month Beta 0.77
  • Price/Sales 9.07
  • Price/Cash Flow 28.13
  • Price/Book 6.88

Options Overview Details

View History
  • Implied Volatility 25.00% ( +0.02%)
  • Historical Volatility 27.55%
  • IV Percentile 74%
  • IV Rank 44.30%
  • IV High 37.97% on 03/11/25
  • IV Low 14.68% on 08/13/24
  • Put/Call Vol Ratio 1.07
  • Today's Volume 11,597
  • Volume Avg (30-Day) 9,873
  • Put/Call OI Ratio 0.74
  • Today's Open Interest 181,252
  • Open Int (30-Day) 207,871

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.67
  • Number of Estimates 10
  • High Estimate 0.68
  • Low Estimate 0.66
  • Prior Year 0.56
  • Growth Rate Est. (year over year) +19.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
93.29 +9.70%
on 03/10/25
105.57 -3.06%
on 03/03/25
+0.78 (+0.77%)
since 02/26/25
3-Month
88.81 +15.23%
on 01/02/25
107.17 -4.51%
on 02/05/25
+10.89 (+11.91%)
since 12/26/24
52-Week
66.80 +53.20%
on 04/22/24
107.17 -4.51%
on 02/05/25
+34.40 (+50.63%)
since 03/26/24

Most Recent Stories

More News
DXCM Stock Gains Following New Data on Upcoming G7 CGM Sensor

DexCom, Inc. DXCM recently unveiled new data for its upcoming G7 15-day continuous glucose monitoring (CGM) sensor at the Advanced Technologies & Treatments for Diabetes (ATTD) conference 2025. With an...

BSX : 102.34 (-0.72%)
COR : 271.39 (+1.08%)
CAH : 133.98 (+0.93%)
DXCM : 72.13 (-1.93%)
BDX Stock Declines Following Class I Classification for Alaris Recall

Becton, Dickinson and Company’s BDX, or popularly known as BD, initiated the recall of its infusion pumps last month after customer reports indicated software issues, potentially leading to inaccurate...

BSX : 102.34 (-0.72%)
BDX : 228.00 (-0.04%)
COR : 271.39 (+1.08%)
CAH : 133.98 (+0.93%)
Does the S&P 500 Rally Make MDT Stock a Buy Amid Easing Trade Tension?

The broader market rally, which pushed the benchmark to a two-week record high yesterday, fueled by tech giants like NVIDIA and Tesla, has provided a much-needed breather for investors. This has potentially...

NVDA : 113.76 (-5.74%)
ABT : 126.61 (+0.80%)
TSLA : 272.06 (-5.58%)
BSX : 102.34 (-0.72%)
MDT : 88.23 (-0.41%)
The Zacks Analyst Blog Boston Scientific, Abbott and Medtronic

For Immediate ReleasesChicago, IL – March 25, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...

ABT : 126.61 (+0.80%)
BSX : 102.34 (-0.72%)
MDT : 88.23 (-0.41%)
Fed's Stagflation Fears Weigh, Yet Growth Factors Make BSX Stock a Buy

Boston Scientific BSX is experiencing a temporary cooling-off period after its strong run in 2024, where the stock climbed 54.5%, banking on robust financial performance and product advancements throughout...

ABT : 126.61 (+0.80%)
BSX : 102.34 (-0.72%)
MDT : 88.23 (-0.41%)
GEHC Stock Falls Despite New Launch to Boost Breast Cancer Diagnosis

GE HealthCare Technologies Inc. GEHC, on Thursday, announced the launch of the Invenia Automated Breast Ultrasound (ABUS) Premium. It is the latest 3D ultrasound product from the company, which is expected...

BSX : 102.34 (-0.72%)
COR : 271.39 (+1.08%)
GEHC : 81.00 (-1.77%)
CAH : 133.98 (+0.93%)
Watch These 5 AI-Powered Healthcare Bigwigs for Portfolio Gains

The medical sector is one of the major adopters of artificial intelligence (AI), which is currently being used to synthesize new compounds for drugs and create devices for more precise measurement and...

ABT : 126.61 (+0.80%)
BSX : 102.34 (-0.72%)
LLY : 826.76 (-3.00%)
NVS : 110.14 (-0.22%)
MDT : 88.23 (-0.41%)
DGX Stock Set to Benefit From New Google Cloud Partnership

Quest Diagnostics Inc. DGX recently announced a collaboration with Google Cloud, owned by the parent holding company, Alphabet GOOGL. The partnership aims to streamline Quest Diagnostics’ data management,...

GOOGL : 165.06 (-3.22%)
DGX : 166.62 (+0.58%)
BSX : 102.34 (-0.72%)
PODD : 264.88 (-2.87%)
GEHC Stock Gains Following Cardiology Solutions Portfolio Expansion

GE HealthCare Technologies Inc. GEHC, on Monday, announced the launch of the AltiX AI.i edition of Mac-Lab, CardioLab and ComboLab. The AltiX AI.i edition are expected to enhance efficiency and precision...

BSX : 102.34 (-0.72%)
COR : 271.39 (+1.08%)
GEHC : 81.00 (-1.77%)
CAH : 133.98 (+0.93%)
GEHC Stock Gains in Pre-Market Following Tie-Up Expansion With NVIDIA

GE HealthCare Technologies Inc. GEHC announced an expansion of its collaboration with NVIDIA Corporation NVDA yesterday. The latest partnership expansion aims to advance AI-driven autonomous solutions...

NVDA : 113.76 (-5.74%)
BSX : 102.34 (-0.72%)
GEHC : 81.00 (-1.77%)
CAH : 133.98 (+0.93%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and...

See More

Key Turning Points

3rd Resistance Point 106.00
2nd Resistance Point 104.74
1st Resistance Point 103.54
Last Price 102.34
1st Support Level 101.08
2nd Support Level 99.82
3rd Support Level 98.62

See More

52-Week High 107.17
Last Price 102.34
Fibonacci 61.8% 91.75
Fibonacci 50% 86.99
Fibonacci 38.2% 82.22
52-Week Low 66.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar